SCM
ORMP icon

SB Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

SB Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.42M Buy
+1,900,000
New +$4.9M 1.98% 18

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SB Capital Management's ORMP Position: Q4 2025 in Review

SB Capital Management opened a new position in Oramed Pharmaceuticals (ORMP) in Q4 2025: 1,900,000 shares worth $5.42M. The stake represents 1.98% of the portfolio and ranks #18 among its holdings.

57 funds tracked by Wall St. Rank hold ORMP as of Q4 2025.

  • SB Capital Management held 1,900,000 shares of Oramed Pharmaceuticals worth $5.42M as of Q4 2025.
  • Oramed Pharmaceuticals was a new SB Capital Management position in Q4 2025.
  • Oramed Pharmaceuticals made up 1.98% of SB Capital Management's portfolio in Q4 2025, its #18 holding.
  • 57 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2025.

Based on SB Capital Management's 13F filing for Q4 2025, filed 20 Feb 2026.